Valneva's Stock: A Tale of Two Vaccine Programs

Valneva shares pressured by Lyme vaccine trial miss, but chikungunya vaccine gains real-world momentum in Brazil. Company reaffirms 2026 revenue guidance.

The Valneva share price currently reflects a dual narrative, caught between promising progress in one vaccine program and unexpected hurdles in another. This divergence was highlighted as the company presented real-world data for its chikungunya vaccine at the World Vaccine Congress in Washington, while simultaneously grappling with the market's reaction to recent clinical trial results for its Lyme disease candidate.

Lyme Disease Candidate Weighs on Investor Sentiment

The more immediate pressure on the stock stems from its Lyme borreliosis vaccine, VLA15. In late March, the Phase III VALOR study revealed efficacy above 70%, yet it narrowly missed a key statistical benchmark related to the confidence interval. This outcome prompted a swift reassessment from analysts at First Berlin Equity Research. Market expert Simon Scholes reduced the firm's price target for Valneva from €6.60 to €4.80, concurrently lowering the estimated probability of regulatory approval from 90% to 67%. Despite this adjustment, a 'buy' recommendation was maintained, citing partner Pfizer's intention to submit applications to both the FDA and EMA before the end of 2026.

Trading at approximately €2.81, Valneva's shares now sit nearly 30% below their 200-day moving average. The revised analyst target still suggests significant potential upside, indicating that the broader market is currently valuing the Lyme disease program's prospects more conservatively than the research firm.

Chikungunya Vaccine Gains Momentum with Field Data

In contrast, the company's chikungunya vaccine, IXCHIQ, is building positive momentum. The focus at the recent congress was on Phase IV data from a pilot initiative in Brazil, conducted in collaboration with the Instituto Butantan. This program has already administered the vaccine to over 12,000 individuals across ten municipalities, with a total scope of 500,000 doses. Brazil granted approval for IXCHIQ in April 2025, becoming the first country with endemic chikungunya to do so. The newly collected real-world evidence is intended to support future regulatory filings in other endemic regions globally.

Financial Outlook and Pipeline Developments

On the financial front, Valneva has reaffirmed its full-year 2026 revenue guidance, projecting a range of €155 million to €170 million. Product sales are expected to contribute between €145 million and €160 million of this total. The company closed the last fiscal year with a cash position of €109.7 million.

Looking further ahead, another catalyst is scheduled for the latter half of 2026. The company anticipates releasing Phase II data for its Shigella vaccine candidate, S4V2. A positive readout from this study could attract renewed investor interest and diversify the clinical pipeline beyond the two headline programs.